Loading
Latest filing published 27 Apr 2023 for Capricor Therapeutics, INC., €868.8M. Read the official filing
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Xavier Avat discloses dealings in Capricor Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 29 June 2022 to 17 April 2023, the count stands at 3 filings.
Both buying and selling appear: 1 purchase worth €5,402, against 2 sales worth €868.8M. Netting one side against the other leaves €868.8M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2023 to date brings no purchases and 2 sales.
The newest entry dates from 27 April 2023: an open-market sale of €868.8M, in Capricor Therapeutics, Inc. The latest purchase dates back some time: it was published 1,564 days ago, on 7 July 2022. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 10 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations